Format

Send to

Choose Destination
Turk J Haematol. 2016 Sep 5;33(3):180-6. doi: 10.4274/tjh.2015.0220. Epub 2015 Aug 6.

The Mutation Profile of Calreticulin in Patients with Myeloproliferative Neoplasms and Acute Leukemia.

Author information

1
Qilu Hospital of Shandong University, Department of Hematology, Shandong, China, Phone: +86 531 82169887, E-mail: daoxinma@sdu.edu.cn.

Abstract

in English, Turkish

OBJECTIVE:

Calreticulin (CALR) plays important roles in cell proliferation, apoptosis, and immune responses. CALR mutations were described recently in Janus kinase 2 gene (JAK2)-negative or MPL-negative primary myelofibrosis (PMF) and essential thrombocythemia (ET) patients. CALR trails JAK2 as the second most mutated gene in myeloproliferative neoplasms (MPNs). However, little is known about CALR mutation in Chinese patients with leukemia. In the present study, a cohort of 305 Chinese patients with hematopoietic neoplasms was screened for CALR mutations, with the aim of uncovering the frequency of CALR mutations in leukemia and MPNs.

MATERIALS AND METHODS:

Polymerase chain reaction and direct sequencing were performed to analyze mutations of CALR in 305 patients with hematopoietic malignancies, including 135 acute myeloid leukemia patients, 57 acute lymphoblastic leukemia patients, and 113 MPN patients.

RESULTS:

CALR mutations were found in 10.6% (12 of 113) of samples from patients with MPNs. CALR mutations were determined in 11.3% (6 of 53), 21.7% (5 of 23), and 9.1% (1/11) of patients with ET, PMF, and unclassifiable MPN, respectively.

CONCLUSION:

We showed that MPN patients carrying CALR mutations presented with higher platelet counts and lower hemoglobin levels compared to those with mutated JAK2. However, all of the leukemia patients had negative results for CALR mutations.

PMID:
26377485
PMCID:
PMC5111462
DOI:
10.4274/tjh.2015.0220
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Galenos Yayinevi Icon for PubMed Central
Loading ...
Support Center